Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 7, 2015, Pages 1242-1252

  Tanaka, Naoki ^a,b   Takahashi, Shogo ^a   Zhang, Yuan ^c   Krausz, Kristopher W ^a   Smith, Philip B ^d   Patterson, Andrew D ^d   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

ATGL; ER stress; Lipotoxicity; PGC1 ; PPAR

Indexed keywords

ACYL COENZYME A DESATURASE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I ALPHA; CD36 ANTIGEN; CD68 ANTIGEN; CHOLINE; DIACYLGLYCEROL; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; FARNESOID X RECEPTOR; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MESSENGER RNA; METHIONINE; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDATE PHOSPHATASE 2A; PHOSPHATIDATE PHOSPHATASE 2C; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL RECEPTOR; DESNUTRIN PROTEIN, MOUSE; FARNESOID X-ACTIVATED RECEPTOR; FIBROBLAST GROWTH FACTOR; PPARGC1A PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL LIPASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; FAT INTAKE; FATTY ACID OXIDATION; FOOD INTAKE; GENOTYPE; IN VITRO STUDY; LIPID STORAGE; LIPOLYSIS; LIVER CELL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPLICATION; DEFICIENCY; DIET; GENETICS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN DEFICIENCY; WHITE ADIPOCYTE;

MURINAE; MUS;

ADIPOCYTES, WHITE; ANIMALS; ANTIGENS, CD36; CELLS, CULTURED; CHOLINE DEFICIENCY; DIET; ENDOPLASMIC RETICULUM STRESS; FIBROBLAST GROWTH FACTORS; HEPATOCYTES; LIPASE; LIPOLYSIS; MALE; METHIONINE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHATIDATE PHOSPHATASE; PPAR ALPHA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84925778793     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.02.012     Document Type: Article

References (46)

1. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 2000, 1492:203-206.
2. Kharitonenkov A., Adams A.C. Inventing new medicines: the FGF21 story. Mol. Metab. 2014, 3:221-229.
3. Adams A.C., Coskun T., Cheng C.C., Farrell L.S.O., Dubois S.L., Kharitonenkov A. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol. Metab. 2013, 2:205-214.
4. Fisher F.M., Kleiner S., Douris N., Fox E.C., Mepani R.J., Verdeguer F., Wu J., Kharitonenkov A., Flier J.S., Maratos-Flier E., Spiegelman B.M. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012, 26:271-281.
5. Hondares E., Iglesias R., Giralt A., Gonzalez F.J., Giralt M., Mampel T., Villarroya F. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 2011, 286:12983-12990.
6. Chartoumpekis D.V., Habeos I.G., Ziros P.G., Psyrogiannis A.I., Kyriazopoulou V.E., Papavassiliou A.G. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 2011, 17:736-740.
7. Ribas F., Villarroya J., Hondares E., Giralt M., Villarroya F. FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signaling. Biochem. J. 2014, 463:191-199.
8. Adams A.C., Yang C., Coskun T., Cheng C.C., Gimeno R.E., Luo Y., Kharitonenkov A. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2013, 2:31-37.
9. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., Moller D.E., Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
10. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
11. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., Hansen B.C., Shanafelt A.B., Etgen G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
12. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., Kharitonenkov A., Bumol T., Schilske H.K., Moller D.E. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013, 18:333-340.
13. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., Gonzalez F.J. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998, 273:5678-5684.
14. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J.K., Gerard R.D., Burgess S.C., Hammer R.E., Mangelsdorf D.J., Kliewer S.A. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
15. Wang T., Shah Y.M., Matsubara T., Zhen Y., Tanabe T., Nagano T., Fotso S., Krausz K.W., Zabriskie T.M., Idle J.R., Gonzalez F.J. Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis. J. Biol. Chem. 2010, 285:7670-7685.
16. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
17. Cyphert H.A., Ge X., Kohan A.B., Salati L.M., Zhang Y., Hillgartner F.B. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J. Biol. Chem. 2012, 287:25123-25138.
18. Cyphert H.A., Alonge K.M., Ippagunta S.M., Hillgartner F.B. Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS One 2014, 9:e94996.
19. Kliewer S.A., Mangelsdorf D.J. Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr. 2010, 91:254S-257S.
20. Ye D., Wang Y., Li H., Jia W., Man K., Lo C.M., Wang Y., Lam K.S., Xu A. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice. Hepatology 2014, 60:977-989.
21. Feingold K.R., Grunfeld C., Heuer J.G., Gupta A., Cramer M., Zhang T., Shigenaga J.K., Patzek S.M., Chan Z.W., Moser A., Bina H., Kharitonenkov A. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 2012, 153:2689-2700.
22. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
23. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
24. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insight. Science 2011, 332:1519-1523.
25. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., Badman M.K., Martinez-Chantar M.L., Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
26. Yilmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Celikel C.A., Ozdogan O., Imeryuz N., Kalayci C., Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur. J. Clin. Investig. 2010, 40:887-892.
27. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., Zhang H., Pan X., Bao Y., Xiang K., Xu A., Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 2010, 53:934-940.
28. Li H., Dong K., Fang Q., Hou X., Zhou M., Bao Y., Xiang K., Xu A., Jia W. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J. Hepatol. 2013, 58:557-563.
29. Tanaka N., Takahashi S., Fang Z.Z., Matsubara T., Krausz K.W., Qu A., Gonzalez F.J. Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochim. Biophys. Acta 2014, 1841:1596-1607.
30. Tanaka N., Matsubara T., Krausz K.W., Patterson A.D., Gonzalez F.J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012, 56:118-129.
31. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
32. Matsubara T., Tanaka N., Krausz K.W., Manna S.K., Kang D.W., Anderson E.R., Luecke H., Patterson A.D., Shah Y.M., Gonzalez F.J. Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis. Cell Metab. 2012, 16:634-644.
33. Cazanave S.C., Elmi N.A., Akazawa Y., Bronk S.F., Mott J.L., Gores G.J. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G236-G243.
34. Cazanave S.C., Mott J.L., Bronk S.F., Werneburg N.W., Fingas C.D., Meng X.W., Finnberg N., El-Deiry W.S., Kaufmann S.H., Gores G.J. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J. Biol. Chem. 2011, 286:39336-39348.
35. Tanaka N., Takahashi S., Matsubara T., Jiang C., Sakamoto W., Chanturiya T., Teng R., Gavrilova O., Gonzalez F.J. Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice. J. Biol. Chem. 2015, 290:3092-3105.
36. Jiang C., Xie C., Li F., Zhang L., Nichols R.G., Krausz K.W., Cai J., Qi Y., Fang Z.Z., Takahashi S., Tanaka N., Desai D., Amin S.G., Albert I., Patterson A.D., Gonzalez F.J. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 2015, 125:386-402.
37. Karaskov E., Scott C., Zhang L., Teodoro T., Ravazzola M., Volchuk A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology 2006, 147:3398-3407.
38. Arner P., Pettersson A., Mitchell P.J., Dunbar J.D., Kharitonenkov A., Rydén M. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett. 2008, 582:1725-1730.
39. Li X., Ge H., Weiszmann J., Hecht R., Li Y.S., Véniant M.M., Xu J., Wu X., Lindberg R., Li Y. Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett. 2009, 583:3230-3234.
40. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
41. Emanuelli B., Vienberg S.G., Smyth G., Cheng C., Stanford K.I., Arumugam M., Michael M.D., Adams A.C., Kharitonenkov A., Kahn C.R. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest. 2014, 124:515-527.
42. Fisher F.M., Chui P.C., Nasser I.A., Popov Y., Cunniff J.C., Lundasen T., Kharitonenkov A., Schuppan D., Flier J.S., Maratos-Flier E. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014, 147:1073-1083.
43. Ong K.T., Mashek M.T., Bu S.Y., Greenberg A.S., Mashek D.G. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology 2011, 53:116-126.
44. Schaap F.G., Kremer A.E., Lamers W.H., Jansen P.L., Gaemers I.C. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 2013, 95:692-699.
45. Jiang S., Yan C., Fang Q.C., Shao M.L., Zhang Y.L., Liu Y., Deng Y.P., Shan B., Liu J.Q., Li H.T., Yang L., Zhou J., Dai Z., Liu Y., Jia W.P. Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem. 2014, 289:29751-29765.
46. Johnson C.L., Weston J.Y., Chadi S.A., Fazio E.N., Huff M.W., Kharitonenkov A., Köester A., Pin C.L. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009, 137:1795-1804.